Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Serum Insulin-like Growth Factor-1 to Albumin Ratio as a Biomarker for Sarcopenia Severity in End-Stage Renal Disease Patients on Hemodialysis
Authors not listed
Sohag University · 2026
Abstract
Sarcopenia is a prevalent and serious complication among patients with End-Stage Renal Disease (ESRD) receiving maintenance dialysis, characterized by progressive loss of skeletal muscle mass, strength, and physical function. It is strongly associated with adverse clinical outcomes, including increased mortality, hospitalization, frailty, and reduced quality of life. The development of sarcopenia in ESRD is multifactorial, involving chronic inflammation, metabolic disturbances, hormonal dysfunction, anorexia, and the catabolic effects of dialysis. Although the 2019 EWGSOP2 guidelines recommend assessment of muscle strength, quantity, and physical performance for diagnosis, routine clinical implementation remains limited due to the need for specialized equipment, time constraints, and variability related to fluid status in dialysis patients. Consequently, there is a growing need for accessible and reliable biochemical markers for early identification of patients at risk.
Insulin-like Growth Factor-1 (IGF-1), an essential anabolic mediator of muscle protein synthesis, is often reduced and functionally impaired in ESRD, contributing to anabolic resistance and muscle wasting. Serum albumin, a conventional indicator of nutritional and inflammatory status, reflects the catabolic and inflammatory processes associated with sarcopenia but lacks specificity when used independently. The IGF-1/Albumin ratio may provide a more integrated representation of the balance between anabolic and catabolic pathways underlying uremic sarcopenia. Therefore, this study aims to evaluate the association between the serum IGF-1/Albumin ratio and the presence and severity of sarcopenia, as defined by EWGSOP2 criteria, in stable outpatient dialysis patients.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-05 MST
Cite this
APA
Anonymous. (2026). Serum Insulin-like Growth Factor-1 to Albumin Ratio as a Biomarker for Sarcopenia Severity in End-Stage Renal Disease Patients on Hemodialysis. <em>Sohag University</em>. https://clinicaltrials.gov/study/NCT07586956
Vancouver
Anonymous. Serum Insulin-like Growth Factor-1 to Albumin Ratio as a Biomarker for Sarcopenia Severity in End-Stage Renal Disease Patients on Hemodialysis. Sohag University. 2026.
BibTeX
@misc{anon2026SerumI,
title = {Serum Insulin-like Growth Factor-1 to Albumin Ratio as a Biomarker for Sarcopenia Severity in End-Stage Renal Disease Patients on Hemodialysis},
author = {Anonymous},
journal = {Sohag University},
year = {2026},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Clinical Interventions in Aging 2018
Open access · CC-BY
Sarcopenia: assessment of disease burden and strategies to improve outcomes
Kasr El Aini Hospital 2021
Open access · US-GOV
The Prevalence of Sarcopenia in a Cohort of Patients With End Stage Kidney Disease on Haemodialysis Patients and Its Correlation With Mortality
Hospices Civils de Lyon 2018
Open access · US-GOV
Impact of Physical Rehabilitation on Sarcopenia Inolder and Chronic Kidney Patients
The University of Hong Kong 2023
Open access · US-GOV
The Effectiveness of an Elastic Band -Based Progressive Resistance Training (EB-PRT) in Improving Sarcopenia and Clinical Outcomes Among Patients With Heart Failure: A Pilot Mixed-method Study
Ankara City Hospital Bilkent 2025
Open access · US-GOV
Evaluation of the Association Between Serum Selenium Levels and Sarcopenia and Frailty in Patients Receiving Maintenance Hemodialysis
International journal of molecular sciences 2026
Open access · OA